|
| |
Charles E. Murry MD PhD
Dept of Pathology
Univ of Washington Sch of Med
Box 357470
Room D-514 HSB
Seattle, WA 98195-7470
murry@u.washington.edu
Biosketch:
Charles
Murry is Professor of Pathology at the University of Washington in Seattle, and
Director of the Center for Cardiovascular Regenerative Biology. He obtained his
Ph.D. and M.D. from Duke University, and did a fellowship in vascular biology at
the University of Washington under Stephen M. Schwartz, M.D., Ph.D. His
laboratory’s research focuses on myocardial infarctions and the heart’s lack of
intrinsic regenerative ability. Work centers on the biology of myocardial
infarction, both in defining the molecular mechanisms that underlie the heart's
normal wound healing processes and in developing molecular and cell-based
approaches to improve infarct repair. They are a multidisciplinary group, doing
basic work in molecular biology and regulation of gene expression, cell biology,
tissue engineering, mouse models of disease, and analyses of human tissues.
More specifically, the Murry Laboratory’s research involve the following: 1)
Stem cell studies that entail both adult and embryonic stem cells, with an aim
to develop cellular approaches to regenerate the heart. In addition to
continuing analysis of human tissues, the goals are to develop mouse models that
allow them to identify the progenitor cells, factors that trigger mobilization
and homing, and identify the pathways that regulate transdifferentiation of the
progenitors to other cell types, particularly cardiomyocytes; 2) ''Molecular
Pharmacology'' for control of cell proliferation studies involving induction of
cell replication in response to a small, synthetic molecule both in vitro and in
vivo. This system may allow control of proliferation after cell grafting, such
that optimal repair of myocardial infarcts can be effected pharmacologically.
This system works well in skeletal muscle cells and endothelial cells, with
extension to control proliferation of stem cell-derived cardiomyocytes; 3)
Tissue engineering for creation of a ''patch'' of contractile tissue ex vivo,
implanted onto an infarcted heart for cardiac repair. Current approaches involve
seeding cells onto synthetic, biodegradable scaffolds and utilizing a ''cells in
gels'' approach, where cells are seeded into hydrophilic gels containing
microencapsulated growth factors and cytokines for timed release; and 4)
Regulation of the heart's intrinsic repair response using a mouse model of
myocardial infarction developed to take advantage of numerous genetic models.
The lab is currently screening knockout strains to define the major mitogens
i.e., bFGF, that regulate endothelial cell and fibroblast proliferation
post-infarction.
Presentation Title:
Regenerating the infarcted heart: holy grail or wholly fiction?
 Back to
ASIP
President's Symposium:
Stem Cells: Differentiation and Involvement in Tissue Remodeling
Back to Symposia
Back to Monday
|
